Was it worth introducing health economic evaluation of innovative drugs in the french regulatory setting : the case of new drugs against Hepatitis C Virus
Fiche du document
2018
- ISIDORE Id: 10670/1.864fb6...
- hal: hal-01907811
- doi: 10.1016/j.jval.2018.08.009
- PII: S1098-3015(18)36143-6
- PUBMED: 30711067
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jval.2018.08.009
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30711067
http://creativecommons.org/licenses/by-nc/ , info:eu-repo/semantics/OpenAccess
Sujets proches
Wellness Personal health Frenchmen (French people) Medications Medicaments Prescription drugs Medicines (Drugs) Pharmaceuticals Medicine (Drugs) Biography--HealthCiter ce document
Valérie Clément et al., « Was it worth introducing health economic evaluation of innovative drugs in the french regulatory setting : the case of new drugs against Hepatitis C Virus », HAL SHS (Sciences de l’Homme et de la Société), ID : 10.1016/j.jval.2018.08.009
Métriques
Partage / Export
Résumé
The paper draws lessons from the recent uptake of health economic evaluation of innovative drugs in the French regulatory framework.Taking the example of new direct-acting antivirals against Hepatitis C virus the paper asks whether and how the Cost-Effectiveness (CE) Opinions issued by the French National Health Authority improve the information available to support the pricing decisions.The results show that CE Opinions bring to the fore 3 issues prone to impact the Incremental Cost Utility Ratio and that were not available to the decision-maker through Clinical Opinions or published CUA: the stage of treatment initiation, the modeling of the disease progression and the uncertainty around the efficacy rates.
